Host Paul Sax, MD, FIDSA, is joined by Libby Hohmann, MD, FIDSA, an ID specialist at Massachusetts General Hospital, director of the Fecal Microbiota Transplant Lab and associate professor of medicine at Harvard Medical School, to discuss the innovative field of microbiome-based therapy, including the latest therapeutics, efficacy in treating COVID-19 and advice on treating patients with C. diff.

This holiday season, you can help strengthen the infectious diseases workforce and support the people who advance patient care and public health every day. All donations to the IDSA Foundation through December 31 are matched up to $50,000. Learn more and double your impact at idsafoundation.org.